近年来，被誉为“魔法子弹”的抗体药物偶联物（ADC）已成为肿瘤治疗中一颗冉冉升起的璀璨新星。其中，第三代ADC药物注射用德曲妥珠单抗（T-DXd），更是在众多创新疗法中脱颖而出，其在乳腺癌治疗的战场上取得了令人瞩目的进展。
DESTINY-Breast系列研究（以下简称“DB研究”）是T-DXd的关键临床研究项目，涵盖了HER2+和HER2低表达、早期和晚期治疗的全程管理。随着T-DXd的问世，它不仅为乳腺癌患者带来了新的希望，也为肿瘤治疗的未来指明了方向。本文将简单介绍T-DXd的创新机制，并全面梳理其在乳腺癌领域的最新研究进展，以飨读者。
独特的结构与作用机制，
筑起疗效与安全性之基
DB系列研究璀璨夺目——梳理
T-DXd在乳腺癌治疗中的最新研究进展
DB系列研究琳琅满目。其中，DB-03研究“开启华章”，它是全球首个头对头对比标准二线治疗T-DM1的III期临床研究，树立了新的治疗标准。DB-04研究则将T-DXd的治疗范围拓展至HER2低表达领域，打破了传统抗HER2治疗的“二元化”治疗格局，为HER2低表达患者提供了有效的抗HER2靶向治疗方案。还有其他DB系列研究正陆续公布结果或正在进行中，具体研究情况见表1。以下将重点展开T-DXd的重要研究及最新研究进展。
图3. DB-06研究设计
图4. HER2-low队列的中位PFS
图5. HER2-ultralow队列的中位PFS和OS
图6. DB-07研究设计
图7. DB-07研究ORR数据
图8. DB-07研究12个月PFS率
图9. BM队列PFS结果
图10.非BM队列ORR结果
小结
参考文献：
[1]Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173-185.
[2]Edoardo C, Giuseppe C. Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate. Expert Opin Investig Drugs. 2024 Aug;33(8):851-865.
[3]Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020 Feb 13;382(7):610-621.
[4]André F, Hee Park Y, Kim SB, et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 May 27;401(10390):1773-1785. doi: 10.1016/S0140-6736(23)00725-0. Epub 2023 Apr 20. Erratum in: Lancet. 2023 Dec 9;402(10418):2196.
[5]Hamiltonc EP, Hurvitz SA, Im SA, et al., Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.ASCO 2024. Abstract # 1025.
[6]Modi S,Jacot W,Iwata H,et al.Trastuzumab deruxtecan(T-DXd）versus treatment of physician's choice(TPC）in patients(pts）with HER2-low unresectable and/or metastatic breast cancer(mBC）:UpDate:survival results of the randomized,phase 3 DESTINY-Breast04 study.2023 ESMO 376O.
[7]Charles E Geyer,et al. Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05).Cancer Res (2022) 82 (4_Supplement): OT1-02-03.
[8]Giuseppe Curigliano, et al. Trastuzumab deruxtecan vs physician's choice of chemotherapy in patients with hormone receptor-positivehuman epidermal growth factor receptor 2 (HER2)-low orHER2-ultralow metastatic breast cancer with prior endocrinetherapy: primary results from DESTINY-Breast06. ASCO 2024. Abstract LBA1000.
[9]Andre F, et al. DESTINY-Breast07:dose-expansion analysis of T-DXd monotherapy and T-DXd + pertuzumab inpatients with previously untreated HER2+ mBC. 2024 ASCO. Abstract 1009.
[10]Komal Jhaveri, Fabrice André et al. Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08). 2023 SABCS Abstract RF02-03.
[11]Tolaney, S.M. et al. Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09. Annals of Oncology, Volume 32, S507 - S508.
[12]Nadia Harbeck,et al.A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11).Cancer Res (2022) 82 (4_Supplement): OT1-12-04.
[13]Lin N, Ciruelos E, Jerusalem G, et al.Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results. 2024 ESMO. Abstract LBA18.
[14]注射用德曲妥珠单抗药品说明书（Baxter Oncology GmbH, 国药准字SJ20230005）
[15]Hu XC, Curigliano G, Yonemori K, et al. Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): Results from DESTINY-Breast06. 2024 ESMO. LBA22.
[16]Saura C, Cortés J, Modi S, et al. Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03. J Clin Oncol 2024;42:1023-1023.
